NuvOx Pharma
Manufacturing · Arizona, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1635 E 18th St, Tucson, Arizona, 85719, ...Phone Number
(520) 624-6688Website
www.nuvoxpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About NuvOx Pharma
NuvOx Pharma is a clinical stage biotech company based in Tucson, Arizona, focused on developing innovative oxygen therapeutics to address life-threatening diseases associated with hypoxia. Their lead product, NanO₂, is currently undergoing clinical trials for conditions such as glioblastoma and stroke, with promising results from previous studies. The company is dedicated to patient safety and improving oxygen flow in the body, aiming to transform lives through their therapeutic advancements. NuvOx is supported by various grants and collaborations, including funding from the National Institute of Neurological Disorders and Stroke and the UK’s National Institute of Health and Care Research.Explore more
Popular SearchesNuvox Pharmanuvox pharma LLCNuVoxImarx Investments LLCNeuvoxSIC Code 28,283NAICS Code 32,325Show moreNuvOx Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NuvOx Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when NuvOx Pharma launches new products
Check out if NuvOx Pharma is spiking on competitors!
Check if NuvOx Pharma has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on NuvOx Pharma recently announced quarterly report
NuvOx Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if NuvOx Pharma had a recent Job posting/layoffs
Funding: Get notified immidiatlly once NuvOx Pharma has new funding data
Congratulate Masked Content for being promoted to Masked Content at NuvOx Pharma
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined NuvOx Pharma as Masked Content
Find 2 more new buyers
Compare Similar Companies to NuvOx Pharma
Compare insights from companies similar to NuvOx Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NuvOx Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NuvOx Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NuvOx Pharma.
NuvOx Pharma financials insights
Gather financial insights about NuvOx Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Grant
$1M
2020
Debt
$150K
NuvOx Pharma Tech Stack
A closer look at the technologies used by NuvOx Pharma
NuvOx Pharma News & Media
NuvOx Pharma LLC Announces Authorization of ARDS Trial from Health Canada
NuvOx Pharma LLC (“NuvOx”) announced that it has received authorization from Health Canada for its EXTEND: novEl oXygen ThErapeutic NanO2 for mild respiratory distress in Phase Ib and ARDS in Phase II Trials. Evan Unger, MD, CEO of NuvOx, said, “Acute Respiratory Distress Syndrome (ARDS) has been an important part of our overall development strategy. We recently expanded our protocol inclusion criteria [PR.com]NuvOx Pharma Announces Issuance of a New Patent
NuvOx Pharma has been issued US Patent No. 11,857,627, entitled “Fractionated Radiotherapy and Chemotherapy with an Oxygen Therapeutic.” [PR.com]NuvOx Announces Publication of Research Article in Cancer Research Communication
NuvOx Pharma announced publication of a research article, “Dodecafluoropentane Emulsion as a Radiosensitizer in Glioblastoma Multiforme” in Cancer Research Communications. https://aacrjournals.org/cancerrescommun/article/3/8/1607/728499. Evan Unger, MD, President and CEO of NuvOx, said, “We are pleased that this article describing the results of our Phase Ib/IIa Glioblastoma (GBM) trial of [PR.com]NuvOx Announces Glioblastoma Patient Treatment for Phase IIb RESTORE Trial
NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, announced that it enrolled and treated the first subject in the Phase IIb RESTORE Trial for newly-diagnosed glioblastoma multiforme (www.ClinicalTrials.gov: NCT03862430). Dr. Evan Unger, CEO and co-founder of NuvOx said, “We are thrilled to start [PR.com]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NuvOx Pharma
Sign Up For FreeTo access detailed company insights
NuvOx Pharma is a clinical stage biotech company based in Tucson, Arizona, focused on developing innovative oxygen therapeutics to address life-threatening diseases associated with hypoxia. Their lead product, NanO₂, is currently undergoing clinical trials for conditions such as glioblastoma and stroke, with promising results from previous studies.... Read More
